A methylcholanthrene-induced glioblastoma of the C57BL/6 inbred mouse strain was used to raise antibodies in C57BL/6 and C57BL/10 inbred mice and in (C57BL/6 X DBA/2) and (C57BL/6 X Balb/c) F1 hybrids. When examined by the cytotoxicity test, these antibodies define a cell-surface component (or components) found exclusively on brain tissue of all mouse strains studied and of several other mammalian species including man. The antigen, named NS-1 (nervous system antigen-i), is present on cells of three of the four mouse-glial-cell tumors tested, but not on the C1300 neuroblastoma, a tumor of neuronal origin. N S-1 occurs in higher concentration in regions of the nervous system richer in white than in gray matter, and in lower than normal concentrations in brains of myelindeficient neurological mutant mice. The concentration of NS-1 gradually increases postnatally and reaches the adult level between the third and fourth week. The existence of more than one allele or genetic locus controlling NS-1 activity is suggested by the occurrence of higher amounts of NS-1 in brains of the A and C57BL/6 than of the Balb/c and DBA/2 mouse strains. NS-1 is the first cellsurface component to be described that is not only unique to nervous tissue, but specific for glial cells.
The mammalian brain is composed of diverse cell populations with different functions. In order to gain insight into these functions at the cellular and molecular levels, individual cells and, as a first approximation, particular classes of cell types must be characterized. An intimately related aim is the separation of subpopulations of nerve cells.
The cell surface is of particular interest in these respects, since it may play an important role in the social behavior of cells during morphogenesis and differentiation (ref. 1 for review, and refs. 2 and 3), and since separation of cells can be achieved with the help of reagents that recognize surface differences [i.e., antibodies, lectins (4) (5) (6) ]. The present study approaches these objectives by exploiting the sensitive and discriminatory capacity of antibodies to define a surface marker which is specific for one particular cell type.
A major difficulty in delineating antigenic surface components that distinguish among classes of brain cells is that the cell populations available as sources of antigen are far from pure (7) (8) (9) (10) (11) . One is caught in a vicious circle since very pure cell populations are needed as antigens in order to raise specific antisera, while at the same time the immunological approach itself is expected in time to provide the desired separations.
We have turned to the use of tumors as sources of antigen because they may retain some properties characteristic of normal cells (12) (13) (14) (15) (16) (17) , because they grow in relatively homogeneous form, and because the cells are available in preparative amounts. The present report utilizes a chemically induced brain tumor of the mouse, the glioma 26 (18-20) , to raise antibodies in mice that characterize a cellhsurface component (or components) that is specific for a glial subpopulation of nervous system cells.
MATERIALS AND METHODS
Mice. All activity of the antiserum was calculated by determining the percentage of dead cells (as judged by trypan blue uptake, 0.16% in 0.9% saline) in the total cell suspension. For absorption, antiserum at a concentration of two to four serial dilutions below the titer endpoint was incubated for 30 min at 40 with tissue homogenate that had been washed three times and contained mostly membrane fragments and a few whole cells without processes. The tissue homogenates were not subjected to enzymatic treatment. The ratio of serum to packed tissue homogenate was 1:1. The activity of the absorbed serum was tested in the cytotoxicity test as outlined above and described in further detail in ref. 22 . Indirect immunofluorescence was carried out (23) with antiserum at various dilutions in medium containing 2% immune-precipitated fetal-bovine serum (Gibco). 1 X 106 trypsinized G26 tumor cells were incubated in 0.05-ml volumes of the diluted antiserum for 30 min at 40, washed twice, and incubated with fluoresceinated rabbit anti-mouse Ig (Hyland Laboratories) at a dilution of 1:10 for another 30 min at 40.
After two washings cells were resuspended in three drops of 50% glycerol in phosphate-buffered saline, pH 7, and examined with a Leitz Orthoplan microscope equipped with an Osram HBO 200W mercury lamp, and BG38 excitor, KP490 interference and K530 barrier filters.
RESULTS
When B/6, B/10, (B/6 X DBA/2)F1, and (B/6 X Balb/c)Fl hybrids are inoculated with the B/6-derived glioma 26, an antigen, NS-1, is recognized that is unique to brain tissue (Fig. 1) . No other normal mouse cells, including the ectodermally derived testicular and epidermal cells, and none of several malignant mouse cell lines absorb cytotoxic activity of anti-NS-1 antiserum using G26 as the indicator cell. The tumors studied, in addition to the leukemia described in Fig. 1 (Fig. 2) . This experiment was performed six times with consistent results.
In order to ascertain the cell types in the nervous system that express NS-1, the following three experiments were performed: (a) determination of NS-1 concentration in a brain region enriched in white matter (tissue taken from the brainstem) and in a brain region enriched in gray matter (tissue taken from the isocortical mantle of the cerebrum, which contains little underlying white matter) (Fig. 3) ; (b) comparison of NS-1 representation in brains of two myelindeficient mutant mice (the sex-linked mutation myelin synthesis deficiency, msd, and the autosomal mutation quaking, qk,) with their normal littermates (Fig. 4) ; and (c) determination of NS-1 content on tumors of neuronal and glial cell origin. Whereas only one neuronal cell tumor [neuroblastoma C1300 (12, 25) ] is at present available in the mouse, three chemically induced glial cell tumors of the B/6 mouse strain could be examined [glioblastoma (14) , glioma 261 (19) , and ependymoblastoma EPA (19) ] (Fig. 3) .
The higher concentration of NS-1 in white than gray matter and the reduced titers in myelin-deficient mutants compared to their littermates suggest that NS-1 may be associated predominantly with glial membranes. Glial-cell-rich regions of normal peripheral nerve taken from the trigeminal nerve trunk also express levels of NS-1 similar to those of whitematter-rich regions of the central nervous system (not shown in figures). Also, three of four glial cell tumors tested carry the antigen, whereas the C1300 neuroblastoma, a tumor of peripheral neuronal origin, does not express it. From the above experiments it cannot be determined, however, which glialcell types carry NS-1 predominantly, though the oligodendroglial and Schwann cells responsible for myelination are likely among them. The fact that the four glioblastomas examined have been classified into different morphological categories (18) (19) (20) points to the possibility that NS-1 is expressed on more than one glial-cell type in the central nervous system. Since the conclusion that NS-1 is a glial-cell-specific antigen is based on absorption of antibody with subsequent titration of its residual complement-dependent cytotoxicity, the question must be asked whether the apparent higher absorptive capacity of white matter as compared to gray matter is real or might reflect a stronger anticomplementary effect of the antiserum that had been in contact with white matter during absorption. Three points argue against this possibility:
(a) The titers of antisera against cell surface antigens like H-2 (22) , Thy-i (0) (25) , and Pc (21) (b) In the cytotoxicity test as performed in these studies the target cells were washed after the antibody had attached and before the complement was added.
(c) The immunofluorescence method does not depend on complement, and gives similar results to those obtained by the cytotoxicity test.
Since myelination is a prominent feature of postnatal glialcell differentiation, and since glial-cell proliferation continues into the first few weeks after birth (26, 27) , it was of interest to determine NS-1 concentrations at various postnatal stages. The antigen is just detectable by the absorption technique on postnatal day zero and reaches the adult level at approximately 4 weeks (Fig. 5) . One cannot say, however, whether this accretion signifies a quantitative increase in glial-surface membranes or a qualitative maturation of already generated cell-surface components, nor can one assess the possible contribution of the many other developmental events proceding during this time period.
The occurrence of NS-1 within different animal species was examined. Fig. 6 shows that NS-1 activity can be detected in all four mammalian species examined (mouse, rat cat, and human). Partial crossreactivity of the human NS-1 equivalent with the antigen of the mouse was determined by ab- (28) , and basic protein of myelin (24) ] that retain a considerable structural constancy during phylogeny. DISCUSSION NS-1, a glial-cell-specific antigen is the first specific cell-surface component to be described with an exclusive representation in the nervous system. Not only is it confined to this one organ, but it seems restricted to a particular class or few classes of cells. This puts it into the category of "differentiation" antigens (31 MBLA (34) , and IVISPCA (35) , all surface antigens of cells in the immune system. Efforts to produce a specific anti-G26 heteroantiserum in the rabbit have failed so far. Several nervous-system-specific cytoplasmic (probably not surfacemembrane-bound) antigenic components have been reported: S-100 (28), 14-3-2 (28), antigen alpha (36), glial acidic fibrillary protein (37), a glycoprotein (38) , and a protein unique to the olfactory bulb (39) . Membrane-bound constituents of subcellular nerve-cell fractions, e.g., synaptosomes, have been detected with serological methods (40) (41) (42) (43) , but stringent evidence for a surface localization of these antigens was not sought. The methods of complement fixation with subcellular membrane preparations (40, 42, 43) 
